FXYD2 and central nervous system cancer: The results showed that the expression of FXYD2 mRNA was higher in patients with a good prognosis, including those with primary glioma (P = 0.00031), oligodendroglioma (P = 5.6e-10), lower WHO grade (P = 0.00011), IDH mutation (P = 2.5e-18), 1p/19q co-deletion (P = 5.3e-12), and Oligodendroglioma, IDH-mutant and 1p/19q-codeleted (P = 2.3e-20).